Cwm, LLC Xencor Inc Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Xencor Inc stock. As of the latest transaction made, Cwm, LLC holds 1,017 shares of XNCR stock, worth $23,370. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,017

Previous 1,671 39.14%

Holding current value

$23,370

Previous $32,000 37.5%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	SELL	$15.7 - $21.65 $10,267 - $14,159	-654 Reduced 39.14%	1,017 $20,000
Q2 2024 Jul 09, 2024	BUY	$18.21 - $24.5 $2,640 - $3,552	145 Added 9.5%	1,671 $32,000
Q1 2024 Apr 05, 2024	BUY	$18.65 - $26.52 $2,778 - $3,951	149 Added 10.82%	1,526 $34,000
Q4 2023 Feb 01, 2024	BUY	$16.53 - $21.42 $18,959 - $24,568	1,147 Added 498.7%	1,377 $29,000
Q3 2023 Oct 11, 2023	SELL	$20.08 - $25.39 $24,296 - $30,721	-1,210 Reduced 84.03%	230 $5,000
Q2 2023 Aug 03, 2023	BUY	$24.77 - $29.9 $13,053 - $15,757	527 Added 57.72%	1,440 $36,000
Q1 2023 Apr 28, 2023	BUY	$25.95 - $36.95 $4,567 - $6,503	176 Added 23.88%	913 $25,000
Q4 2022 Feb 01, 2023	BUY	$24.79 - $30.86 $619 - $771	25 Added 3.51%	737 $19,000
Q3 2022 Oct 27, 2022	BUY	$24.62 - $32.44 $4,702 - $6,196	191 Added 36.66%	712 $18,000
Q2 2022 Jul 28, 2022	BUY	$19.74 - $29.01 $5,073 - $7,455	257 Added 97.35%	521 $14,000
Q1 2022 Apr 21, 2022	SELL	$26.68 - $41.63 $7,363 - $11,489	-276 Reduced 51.11%	264 $7,000
Q4 2021 Jan 31, 2022	BUY	$33.67 - $43.44 $18,181 - $23,457	540 New	540 $22,000

Others Institutions Holding XNCR

# of Institutions

215

Shares Held

71.5M

Call Options Held

2.5K

Put Options Held

7.9K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.37B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account